Moreover, a meta-analysis of the association between cfDNA and the prognosis of pancreatic cancer patients concluded that certain mutations (KRAS, ERBB2-exon17, and KRASG12V), ctDNA presence, hypermethylation and higher concentration of cfDNA were associated with worse survival in patients with pancreatic cancer [10]. This evidence concerns the gene KRAS and familial pancreatic carcinoma.